Boston Scientific Corp., Natick, Mass., agreed to acquire the rest of Rubicon Medical Corp., Salt Lake City, in a deal valued at more than $155 million. Exercising a 2003 purchase option, Boston Scientific said it would pay $71.7 million up front for the 82% of Rubicon it doesn't already own, plus $83.7 million as various production and performance milestones are met. Rubicon makes the Rubicon Filter, a device that removes clots and other blood-borne debris from veins and arteries. The device was approved Thursday for sale in Europe; it has yet to receive approval from the U.S. Food and Drug Administration. On Thursday, however, Boston Scientific won FDA approval of its Liberte bare-metal coronary stent-implanting system, which the company said serves as the platform for its next-generation drug-eluting stent, Taxus Liberte. Taxus is the company's main product and the top-selling drug-eluting stent in the U.S. -- by Laura B. Benko
Boston Scientific to buy maker of clot-clearing device
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.